Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: axial who wrote (10502)	8/9/2002 1:39:31 PM
From: Greg Spendjian	Read Replies (3) \| Respond to of 14101

WF-10 does indeed appear to have awesome potential as long as some of the previous results are confirmed. It is understandable that people on chat lines like Stockhouse might miss the opportunity. But what gives one a cautionary pause is that none of the big pharmas have jumped to the bait. Presumably the strategists at companies like Merck, Pfizer, or Novartis have looked at and analyzed all the information on WF-10. If that is the case, why aren't they banging on DMX's door (or previously on Oxo's door)? I simply have difficulty believing that they are unaware of the information about it. Anyway ... I'm not trying to downplay the WF-10 possibilities here. I'm just trying to explain how come we on this board are the only brilliant ones ... when it comes to seeing them.

To: axial who wrote (10502)	8/9/2002 1:57:27 PM
From: Josephus	Respond to of 14101

"It is mind boggling to me what people are missing here." Therein may be the crux. When I first heard of WF-10 and Dimethaid (so many years ago it's difficult to remember) it was in the same forum of other "mind boggling" opportunities that were later proved to be, literally, dust. Even though we haven't completely lost the ability to dream, our dreams are now tempered by experience - the wisdom of old, un-wealthy men. ...just keep dropping those quarters in the turtle bank. Jody_/)_

To: axial who wrote (10502)	8/9/2002 2:01:18 PM
From: Montana Wildhack	Respond to of 14101

Jim, Joe, I'm not as convinced that DMX will partner up to get WF10 through the FDA. For one thing, my understanding is that the sales effort required to sell to the AIDS market is much less due to the concentrated buying infrastructure. I also see JNJ and US placement(s) as providing tons of cash to move on all fronts. This isn't optimism. There will be small upfront from JNJ I estimate above $20M and one stated reason for the US placement is liquidity - so its no doubt somewhere in the 3-5 million share range. Since it follows that we must meet minimum listing require- ments, this would raise no less than 15-25 million more US and I suspect it will be higher. Taking the midpoints and minimums its no less than $60 million Cdn within the next 6 months or so. I loved Greg's line about who's brilliant. I just don't see mediocre P3 results as statistically probable. We'll see I suppose. It sounds like we have a meeting to discuss the application with the FDA. Wolf

To: axial who wrote (10502)	8/9/2002 4:07:46 PM
From: J-R	Read Replies (1) \| Respond to of 14101

Jim, I can't believe it, either. I commented on SH about the number of click-throughs on di7026'2 posts. I agree wholehartedly - there is a lot of potential in WF10. That being said, don't put a whole lot of faith in the # of clickthru's on Stockhouse. They are actually multiplied by 9x... Every amount of clickthru's is divisible wholly by nine... Just thought I'd point that out as someone pointed it out to me... As I said above - unreal potential with WF10. That is what scares me though - with that unreal potential, shouldn't DMX be reflecting some of that potential in its shareprice??? It isn't, and that puts up a caution flag for me... the old "sounds to good to be true" story... JMO, FWIW.. J-R